Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06065462
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Ovarian Clear Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dostarlimab — DRUG
    Given by vein (IV)
  • LB-100 — DRUG
    GIven by vein (IV)

Study Details

To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma

Key Dates

Start date
Nov 10, 2023
Status verified
Dec 2025
Primary completion
Oct 1, 2027
Completion
Oct 1, 2027

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dostarlimab + LB-100
    Dostarlimab will be given by vein over about 30 minutes on Day 1 of each cycle. LB-100 will be given by vein on Days 1-3 of each cycle. The first doses will be given over about 2 hours. After that, doses may be given over as little as 30 minutes.

Primary Outcome Measure

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030
Ljiljana Milojevic
[email protected]
713-792-8578
Amir Jazaeri, M D (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
M D Anderson Cancer Center· Houston, TX

Related Studies